Can an Oral Tau-Targeting Drug Slow Early Alzheimer's…

Can an Oral Tau-Targeting Drug Slow Early Alzheimer's Disease? Researchers have evaluated whether ceperognastat, an investigational oral drug designed to target tau pathology, can slow disease progression in people with early symptomatic Alzheimer's disease. The findings, published in JAMA, suggest that the treatment did not provide a meaningful clinical benefit, despite targeting one of the key proteins involved in Alzheimer's disease. Why Target Tau? While amyloid plaques have long been a major focus of Alzheimer's research, tau protein accumulation is closely associated with neuronal damage, cognitive decline, and disease progression. Ceperognastat works by inhibiting O-linked N-acetylglucosaminidase (OGA), an enzyme involved in tau regulation, with the goal of slowing tau-related neurodegeneration. About the Study: The phase 2, randomized, double-blind, placebo-controlled trial enrolled 327 adults aged 60 to 85 years with early symptomatic Alzheimer's disease and low to medium tau burden on PET imaging. Participants from 72 cente